Published online May 27, 2022. doi: 10.4240/wjgs.v14.i5.409
Peer-review started: December 30, 2021
First decision: March 10, 2022
Revised: March 12, 2022
Accepted: April 26, 2022
Article in press: April 26, 2022
Published online: May 27, 2022
Processing time: 145 Days and 23 Hours
Recurrent hepatocellular carcinoma can be effectively treated with repeated liver resection (HCC). For recurrent HCC, few studies have compared the outcomes of laparoscopic repeat hepatectomy (LRH) with open repeat hepatectomy (ORH), and even fewer have included cirrhotic patients.
Currently, there is a lack of evidence of the effectiveness of LRH for the treatment of recurrent HCC in cirrhotic patients.
This study aimed to compare the short-term and long-term outcomes for cirrhotic patients with LRH and ORH for recurrent HCC. The study was intended to provide insights on performing LRH for cirrhotic patients with recurrent HCC.
A prospectively collected database identified all patients undergoing repeat hepatectomy for recurrent HCC between May 2006 and June 2021. Recurrent HCC with tumours > 7 cm were excluded. Patient demographics, operative details, perioperative outcomes, pathologic details, disease-free survival (DFS) and overall survival (OS) associated with LRH and ORH were compared.
Cirrhosis was histologically diagnosed in 62.7% of our patients and more than 90% were hepatitis B carriers. Blood loss (median 300 mL vs 200 mL, P = 0.013) and length of hospital stay (median 5 d vs 7 d, P = 0.003) were significantly better in the LRH group. There were no significant differences in the 1-, 3- and 5-year OS and DFS rates between the LRH and ORH groups.
Even in patients with cirrhosis, laparoscopic liver resection for recurrent HCC was associated with decreased blood loss, a shorter hospital stay, and equivalent overall and DFS to open surgery.
Laparoscopic re-resection should be considered for patients with recurrent HCC of less than or equal to 7 cm in size that develop subsequent to a previous hepatectomy. However, larger studies or randomised controlled trials should be conducted to confirm the advantages of LRH for the management of recurrent HCC.